title: Characterization of HIV-1 genotypes and antiretroviral drug-resistance mutations among patients in Burkina Faso.
abstract: The purposes of this study were: (1) to describe the genetic variability of HIV strains found in Burkina Faso, (2) to characterize non-B HIV strains mutation profiles selected by ARVs and (3) to detect possible resistances induced by ARV drugs. From 30 October 2002 to 20 November 2003, 132 HIV 1-positive patients taking Highly Active Antiretroviral Therapy (HAART) for more than one year in Bobo-Dioulasso and Ouagadougou were included. T-CD4+ lymphocytes count was done using Dynabeads technique while genotypic test and ARV-resistance tests were conducted using Pol sequencing that codes for reverse transcriptase reverse, integrase and protease. Due to undetectable viremia, 86 samples out of 132 could not be characterized. Whereas in the 46 others that had a viral load exceeding 1000 copies mL(-1), the following HIV-1 subtypes were identified: CRF06 (54,55%); CRF02(38,63%); CRF01 (4,55%) and subtype A (2,27%). In addition, several mutations related to PI, NRTI and NNRTI resistance were isolated in 27 samples. This study found a huge genetic HIV-1 polymorphism in Burkina Faso. The level of acquired resistance to ARV after one year of treatment amounted 20.4%. These results clearly show that there is imperative need to set up an ARV resistance surveillance network in Burkina Faso to guide treatment strategies and follow the extension of the phenomenon in the country.
authors: Centre MURAZ Bobo-Dioulasso, Burkina Faso.
authors: T S
authors: TS
authors: Kagone
authors: H
authors: H
authors: Hien
authors: N
authors: N
authors: Meda
authors: P S
authors: PS
authors: Diagbouga
authors: A
authors: A
authors: Sawadogo
authors: J
authors: J
authors: Drabo
authors: M
authors: M
authors: Peeters
authors: L
authors: L
authors: Vergne
authors: E
authors: E
authors: Delaporte
authors: C
authors: C
authors: De Souza
authors: M
authors: M
authors: Gbeassor
authors: J
authors: J
authors: Simpore
mesh_terms: D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001483:Base Sequence; D002050:Burkina Faso; D003430:Cross-Sectional Studies; D004279:DNA, Viral / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D005814:Genes, Viral; D015751:Genes, pol; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010802:Phylogeny; D011110:Polymorphism, Genetic; D055815:Young Adult
chemical_list: D004279:DNA, Viral